The rise of SGLT2 inhibitors: the time is now for cardiovascular specialists to lead the charge.

Cardiovascular (CV) disease continues to be the leading cause of death and disability across the globe and is especially burdensome on patients with diabetes mellitus (DM). [1] Numerous cellular an...